<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04288999</url>
  </required_header>
  <id_info>
    <org_study_id>JCOG1801</org_study_id>
    <nct_id>NCT04288999</nct_id>
  </id_info>
  <brief_title>Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer</brief_title>
  <acronym>JCOG1801</acronym>
  <official_title>JCOG1801: A Phase III Randomized Controlled Trial Comparing Surgery Plus Adjuvant Chemotherapy With Preoperative Chemoradiotherapy Followed by Surgery Plus Adjuvant Chemotherapy for Locally Recurrent Rectal Cancer (RC-SURVIVE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center Hospital East</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Japan Clinical Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Japan Agency for Medical Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center Hospital East</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      JCOG1801 is a randomized phase III trial which was initiated in Japan in August 2019 to
      confirm the superiority of preoperative chemoradiotherapy followed by surgery plus adjuvant
      chemotherapy for local relapse-free survival over standard treatment, i.e. surgery plus
      adjuvant chemotherapy, for previously non-irradiated locally recurrent rectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In all, 110 patients from 43 Japanese institutions will be recruited over a period of 6
      years. Eligible patients would be registered and randomly assigned to each group with an
      allocation ratio of 1:1. The primary endpoint is local relapse-free survival. The secondary
      endpoints are overall survival, relapse-free survival, proportion of local relapse,
      proportion of distant relapse, proportion of patients with pathological R0 resection,
      response rate of preoperative chemoradiotherapy (preoperative chemoradiotherapy arm),
      pathological complete response rate (preoperative chemoradiotherapy arm), proportion of
      patients who completed the protocol treatment, incidence of adverse events (adverse
      reactions), and quality of life after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 2028</completion_date>
  <primary_completion_date type="Anticipated">August 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Locally recurrent free survival</measure>
    <time_frame>3-years after registration</time_frame>
    <description>the period from registration in the trial to either the first event of local relapse or death from any cause and censored at the last date of contact for a living patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3-years after registration</time_frame>
    <description>s the time from registration to death from any cause and censored at the last date of contact for a living patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival (RFS)</measure>
    <time_frame>3-years after registration</time_frame>
    <description>the time from registration to either the first incidence of relapse or death from any cause and censored at the last date of contact for a living patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local relapse rate</measure>
    <time_frame>3-years after registration</time_frame>
    <description>Proportion of local relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant relapse rate</measure>
    <time_frame>3-years after registration</time_frame>
    <description>Proportion of distant relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>Proportion of patients with pathological R0 resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate of preoperative chemoradiotherapy (preCRT)</measure>
    <time_frame>before surgery</time_frame>
    <description>Response rate of preCRT (arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response rate</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>Pathological complete response rate (arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completeness of the protocol treatment</measure>
    <time_frame>8 months after surgery</time_frame>
    <description>Proportion of patients who completed the protocol treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>3-years after surgery registration</time_frame>
    <description>Incidence of adverse events (adverse reactions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL</measure>
    <time_frame>3-years after registration</time_frame>
    <description>QOL after surgery based on the Trial Outcome Index-Physical/Functional/Colorectal (TOI-PFC) [0(better)-84(worse)]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Rectal Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy
Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)
Adjuvant chemotherapy: CAPOX (capecitabine+oxaliplatin) or mFOLFOX6 (5-fluorouracil+l-leucovorin+oxaliplatin) or capecitabine or 5-fluorouracil (FU) +l-leucovorin (LV)
CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)
mFOLFOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.
Capecitabine: 2000 mg/m2/day, twice daily, days 1-14
5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgery plus Adjuvant chemotherapy
Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV
CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)
mFOLFOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.
Capecitabine: 2000 mg/m2/day, twice daily, days 1-14
5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV
CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)
mFOLOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.
Capecitabine: 2000 mg/m2/day, twice daily, days 1-14
5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Preoperative radiotherapy</intervention_name>
    <description>Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy
Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Capecitabine plus radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Procedure</intervention_name>
    <description>Surgery for Locally Recurrent Rectal Cancer (LRRC) will be performed within 42 days from registration for the patients in arm A, and between days 56 and 98 from the completion of the preCRT for the patients in arm B.
Appropriate surgical procedure will be performed to achieve R0 resection, such as low anterior resection, super low anterior resection, intersphincteric resection, Hartmann procedure, rectal amputation, pelvic exenteration, tumor resection, or lateral lymph node dissection</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histopathologically proven adenocarcinoma or adenosquamous carcinoma on the resected
             specimen of the initial rectal cancer or endoscopic biopsy from the initial rectal
             cancer.

          2. The main tumor location of the initial rectal cancer is upper, middle or lower rectum,
             or anal canal.

          3. Either of the following treatments was performed for the initial rectal cancer, and
             classified as R0/1 or ER (Endoscopical R)0/1 on pathological diagnosis.

             i) Surgical resection (including local resection, with or without lymph node
             dissection).

             ii) Endoscopic resection.

          4. Patients with distant metastasis during or after treatment for the initial rectal
             cancer, and radical surgical resection or radical radiotherapy performed more than 168
             days before registration is eligible.

          5. Recurrent rectal cancer diagnosed by any of the following modalities after treatment
             for the initial rectal cancer.

             i) The recurrent lesion is pathologically diagnosed. ii) Diagnosed as local recurrence
             by more than two modalities among contrast-enhanced CT, contrast-enhanced MRI, or
             positron emission computed tomography (PET).

             iii) Chronological progression of the lesion seen on more than one modality among
             contrast-enhanced CT, MRI, or PET.

          6. The main tumor location is within pelvis as seen on contrast-enhanced CT and MRI if
             recurrent lesion is multiple, or recurrent lesions spread outside of pelvis
             continuously.

          7. LRRC is diagnosed with no following condition. i) Judged as resectable endoscopically.
             ii) Depth of invasion within the muscularis propria as seen on contrast-enhanced CT,
             MRI, or PET in case of recurrence inside the intestine iii) Solitary ovarian
             metastasis. iv) Recurrence of the common iliac lymph node alone.

          8. LRRC is diagnosed as resectable, and all the following conditions must be fulfilled:

             i) No distant metastasis on contrast-enhanced CT (cM0). ii) Estimated circumferential
             resection margin ＞0 mm. iii) Leg amputation not required. iv) Preservation of the
             first sacral nerve possible.

          9. No prior surgery for recurrent rectal cancer.

         10. No prior pelvic irradiation for any malignancies.

         11. A patient who has received systemic chemotherapy for any malignancies and the final
             dose was administered more than 14 days ago.

         12. Age at registration is 20 to 80 years old.

         13. Eastern Cooperative Oncology Group (ECOG) performance status is 0 or 1.

         14. Measurable lesion is not mandatory.

         15. Adequate oral intake.

         16. Sufficient organ function. i) Neutrophil count &gt;= 1,500/mm3 ii) Hemoglobin &gt;= 9.0 g/dL
             iii) Platelet count &gt;= 100,000/mm3 iv) Total Bilirubin =&lt; 2.0 mg/dL v) Aspartate
             aminotransferase (AST) =&lt; 100 U/L vi) Alanine Aminotransferase (ALT) =&lt; 100 U/L vii)
             Cr =&lt; 1.5 mg/dL

         17. Open surgery or laparoscopic surgery is planned.

         18. Written informed consent is obtained.

        Exclusion Criteria:

          1. Synchronous or metachronous (within 5 years) malignancies except cancer with 5-year
             relative survival rate of 95% or more such as carcinoma in situ, intramucosal tumor,
             or early stage cancers.

          2. Infections requiring systemic treatment.

          3. Body temperature higher than 38 degrees Celsius at registration.

          4. Pregnant female, female within 28 days post-parturition, or lactating mother. Men with
             partners planning conception in the near future.

          5. Severe psychological disease.

          6. Continuous systemic corticosteroid or immunosuppressant treatment.

          7. Uncontrollable diabetes mellitus.

          8. Uncontrollable hypertension.

          9. Unstable angina pectoris, or history of myocardial infarction within 6 months.

         10. Uncontrollable valvular disease, dilated cardiomyopathy, or hypertrophic
             cardiomyopathy.

         11. Positive serum Hepatitis B (HB)s antigen or serum Hepatitis C Virus (HCV) antibody.

         12. Positive serum HIV antibody.

         13. Interstitial pneumonia, pulmonary fibrosis, or severe emphysema on chest CT.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masaaki Ito, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center Hospital East</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuichiro Tsukada, MD,PhD</last_name>
    <phone>+80-4-7133-1111</phone>
    <email>yutsukad@east.ncc.go.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Masaaki Ito, MD, PhD</last_name>
    <phone>+80-4-7133-1111</phone>
    <email>maito@east.ncc.go.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chiba Cancer Center</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nobuhiro Takiguchi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gifu University School of Medicine</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazuhiro Yoshida</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University International Medical Center</name>
      <address>
        <city>Hidaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shigeki Yamaguchi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hospital</name>
      <address>
        <city>Hirakata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mitsugu Sekimoto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hiroshima City Asa Citizens Hospital</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mamoru Shimomura</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hiroshima City Hospital</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masazumi Okajima</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shimane University Faculty of Medicine</name>
      <address>
        <city>Izumo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshitsugu Tajima</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ishikawa Prefectural Central Hospital</name>
      <address>
        <city>Kanazawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroyuki Bando</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masaaki Ito</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saitama Medical Center, Saitama Medical University</name>
      <address>
        <city>Kawagoe</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hideyuki Ishida</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kochi Health Sciences Center</name>
      <address>
        <city>Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryo Inada</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hideo Baba</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital</name>
      <address>
        <city>Kurashiki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazuyuki Kawamoto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kurume University School of Medicine</name>
      <address>
        <city>Kurume</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshito Akagi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center</name>
      <address>
        <city>Matsuyama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takaya Kobatake</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyorin University Faculty of Medicine</name>
      <address>
        <city>Mitaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tadahiko Masaki</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University</name>
      <address>
        <city>Morioka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Koki Otsuka</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nagoya University Graduate School of Medicine</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Keisuke Uehara</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasumasa Takii</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine</name>
      <address>
        <city>Nishinomiya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naohiro Tomita</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Okayama Saiseikai General Hospital</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshihiro Akazai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Osaka National Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takeshi Kato</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka City General Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiyoshi Maeda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yusuke Nishizawa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sapporo-Kosei General Hospital</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hideki Yamagami</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miyagi Cancer Center</name>
      <address>
        <city>Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kou Miura</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akio Shiomi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka University Graduate School of Medicine</name>
      <address>
        <city>Suita</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsunekazu Mizushima</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suita Municipal Hospital</name>
      <address>
        <city>Suita</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shu Okamura</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka Medical College</name>
      <address>
        <city>Takatsuki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junji Okuda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Defense Medical College</name>
      <address>
        <city>Tokorozawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hideki Ueno</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yukihide Kanemitsu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toho University Ohashi Medical Center</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshihisa Saida</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toho University Omori Medical Center</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kimihiko Funahashi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical and Dental University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yusuke Kinugasa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akihiko Tsuchida</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keiichi Takahashi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tochigi Cancer Center</name>
      <address>
        <city>Utsunomiya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shin Fujita</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yamagata Prefectural Central Hospital</name>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshihiko Sato</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manabu Shiozawa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yokohama-shi Nanbu Hospital</name>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tadao Fukushima</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Medical Center</name>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Watanabe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oita University Faculty of Medicine</name>
      <address>
        <city>Yufu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masafumi Inomata</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ogaki Municipal Hospital</name>
      <address>
        <city>Ōgaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuichi Takayama</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gunma Prefectural Cancer Center</name>
      <address>
        <city>Ōta</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hitoshi Ojima</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://jrct.niph.go.jp/en-latest-detail/jRCTs031190076</url>
    <description>Japan Registry of Clinical Trials</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rectal cancer</keyword>
  <keyword>Locally recurrent rectal cancer</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Surgery</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

